Vivitrex (Alkermes/Cephalon).
Vivitrex, an injectable, sustained-release formulation of the opioid antagonist naltrexone, is being developed by Alkermes and Cephalon for the potential once-monthly treatment of alcoholism and opiate use disorder. Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005.